Drug Trial Radar · NCT05320588
A Study in Patients With Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
332
Planned (sponsor's estimate)
Start
Mar 25, 2022
Primary completion
Apr 2024
Study completion Apr 2027
Sponsor
- Lead sponsor
- BiOneCure Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Conditions
- Advanced Cancer
- Advanced Solid Tumor
- Cancer
- Oncology
Interventions
BIO-106Drug
BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)
PembrolizumabDrug
Programmed death receptor-1 (PD 1)-blocking antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)Time frame: 1 year
- Incidence and nature of dose-limiting toxicities (DLTs) - (Phase 1)Time frame: up to 21 days
- Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)Time frame: 1 year
- Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 2)Time frame: 2 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
NEXT Oncology Austin
Austin, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.